Plasma Tau Biomarkers for Alzheimer's Disease Staging
Laia Montoliu‐Gaya(Sahlgrenska University Hospital), Oskar Hansson(Eli Lilly (United States)), Gunnar Brinkmalm(University of Gothenburg), Sebastian Palmqvist(Skåne University Hospital), Erik Stomrud(Lund University), Kaj Blennow(Sahlgrenska University Hospital), Juan Lantero‐Rodriguez(University of Gothenburg), Sophia Weiner(Institute of Neurobiology), Niklas Mattsson(Malmö University), Gemma Salvadó(Lund University), Johanna Nilsson(University of Gothenburg), Shorena Janelidze(Lund University), Johan Gobom(Sahlgrenska University Hospital), Henrik Zetterberg(University of Wisconsin System), Nicholas J. Ashton(King's College London)
Cited by 0
Related Papers
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment
|Journal of Internal Medicine|2004|5k
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
|Alzheimer s & Dementia|2024|2.3k
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
|New England Journal of Medicine|2014|2k
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria
|Alzheimer s & Dementia|2016|1.9k